Tech Company Financing Transactions
Artax Biopharma Funding Round
On 5/12/2022, Artax Biopharma raised $26 million in funding from Eli Lilly and Company, Sound Bioventures and Advent Life Sciences.
Transaction Overview
Company Name
Announced On
5/12/2022
Transaction Type
Venture Equity
Amount
$26,000,000
Round
Undisclosed
Investors
Eli Lilly and Company (Lead Investor)
Sound Bioventures (Lead Investor)
private investors (Belinda Termeer)
Proceeds Purpose
The company intends to use the funds to develop AX-158, its first oral small molecule immunomodulating agent.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Brdwy.
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Not Recorded
Overview
This is the website of Artax BioPharma, a development stage biopharmaceutical company focused on the fields of autoimmune and inflammatory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Alan Walts
Chief Executive Officer
Damià Tormo
Chief Medical Officer
Christopher VanDeusen
Chief Scientific Officer
Balbino Alarcón
VP - R & D
Andrew Gagete
Browse more venture capital transactions:
Prev: 5/12/2022: 6K venture capital transaction
Next: 5/12/2022: BalkanID venture capital transaction
Share this article
Where The Data Comes From
We do our best to record tech company VC transactions. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs